Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Ras Gene02:38

The Ras Gene

6.3K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.3K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

5.6K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.6K
Cancer Vaccines01:30

Cancer Vaccines

410
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
410
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

4.0K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.0K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer Prevention/Interception Agent Development.

Cancer prevention research (Philadelphia, Pa.)·2025
Same author

Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer.

Cancer prevention research (Philadelphia, Pa.)·2025
Same author

Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Enhancing Radiation Therapy Response in Prostate Cancer Through Metabolic Modulation by Mito-Lonidamine: A <sup>1</sup>H and <sup>31</sup>P Magnetic Resonance Spectroscopy Study.

International journal of molecular sciences·2025
Same author

Preventive Treatment with a CD73 Small Molecule Inhibitor Enhances Immune Surveillance in K-Ras Mutant Pancreatic Intraepithelial Neoplasia.

Cancer prevention research (Philadelphia, Pa.)·2024
Same author

Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.

Journal of cell science·2024
Same journal

Optimization of RNA Sequencing Workflow in Brush Swabs of Oral Squamous Cell Carcinoma.

Cancer prevention research (Philadelphia, Pa.)·2026
Same journal

Proteomic analysis of sphingolipid metabolic enzymes with risk of bladder cancer incidence and mortality in the Atherosclerosis Risk in Communities (ARIC) Study.

Cancer prevention research (Philadelphia, Pa.)·2026
Same journal

Cancer Screening Adherence in the US by Smoking and Vaping Status, 2023.

Cancer prevention research (Philadelphia, Pa.)·2026
Same journal

Advancing Gastric Cancer Chemoprevention: Early Signals and Ongoing Challenges.

Cancer prevention research (Philadelphia, Pa.)·2026
Same journal

Will they use it? Patient and provider acceptance of chatbot screening and counseling for hereditary cancer syndromes in a geographically underserved population.

Cancer prevention research (Philadelphia, Pa.)·2026
Same journal

The Clinical Application of Refined Risk Estimates (caRe) Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial.

Cancer prevention research (Philadelphia, Pa.)·2026
See all related articles

Related Experiment Video

Updated: Jul 23, 2025

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.1K

Primary Prevention and Interception Studies in RAS-Mutated Tumor Models Employing Small Molecules or Vaccines.

Konstantin H Dragnev1, Ronald A Lubet2, Mark Steven Miller2

  • 1Dartmouth Cancer Center, Lebanon, New Hampshire.

Cancer Prevention Research (Philadelphia, Pa.)
|July 19, 2023
PubMed
Summary
This summary is machine-generated.

Targeting RAS-mutated cancers is challenging, but prevention and interception are promising. Various agents, including glucocorticoids, RXR agonists, and COX inhibitors, effectively prevent or intercept RAS-mutated tumors across different organs.

More Related Videos

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

23.4K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.5K

Related Experiment Videos

Last Updated: Jul 23, 2025

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.1K
Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

23.4K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.5K

Area of Science:

  • Oncology
  • Cancer Prevention
  • Molecular Biology

Background:

  • Therapeutic targeting of RAS-mutated cancers remains difficult.
  • Prevention and interception strategies (treatment before or during preinvasive stages) show preclinical promise.
  • RAS pathway mutations are common drivers in various human cancers.

Purpose of the Study:

  • To evaluate the efficacy of various agents in preventing or intercepting RAS-mutated tumors across different organs.
  • To explore non-RAS-specific agents for their potential in cancer prevention and interception.
  • To investigate combination therapies for enhanced prevention of RAS-driven cancers.

Main Methods:

  • Utilized preclinical cancer models, including A/J mouse lung, rat azoxymethane-induced colon, and N-nitroso-N-methylurea-induced rat breast models.
  • Administered various agents such as glucocorticoids, retinoid X receptor (RXR) agonists, cyclooxygenase (COX) 1/2 inhibitors, EGFR inhibitors, and selective estrogen receptor modulators.
  • Assessed tumor development and response to treatment in KRAS-mutated, HRAS-mutated, and wild-type tumor contexts.

Main Results:

  • Glucocorticoids and RXR agonists were effective in preventing/intercepting KRAS-mutated lung tumors, irrespective of specific mutations.
  • COX 1/2 inhibitors and difluoromethylornithine showed efficacy in preventing/intercepting both KRAS-mutated and wild-type colon tumors.
  • Combination therapy with COX and EGFR inhibitors nearly eliminated pancreatic tumors in transgenic mice.
  • Selective estrogen receptor modulators, aromatase inhibitors, EGFR inhibitors, and RXR agonists were effective in HRAS-mutated breast tumors, while tipifarnib preferentially inhibited HRAS-mutant tumors.

Conclusions:

  • Many agents not directly targeting the RAS pathway demonstrate organ-specific efficacy in preventing or intercepting RAS-mutated tumors.
  • Prevention and interception represent viable strategies for managing RAS-driven cancers.
  • Future research could explore vaccines targeting KRAS as an alternative prevention approach.